Pharmaceutical Safety Assessment Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The pharmaceutical safety assessment field has seen substantial progress recently, driven by advancements in drug development and regulatory requirements. As pharmaceutical companies strive to ensure drug efficacy and patient safety, the market for safety evaluation continues to expand rapidly. Below, we explore the market's size, growth influences, key players, emerging trends, and segmentation to provide a comprehensive understanding of this evolving industry.

Pharmaceutical Safety Assessment Market Size and Growth Forecast
The pharmaceutical safety assessment market has demonstrated robust growth and is anticipated to continue this trajectory. From a value of $11.32 billion in 2025, the market is projected to reach $12.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. This surge in recent years can be attributed to the expansion of pharmaceutical research and development pipelines, heightened regulatory scrutiny on drug safety, increasing volumes of preclinical and clinical testing, broader adoption of in-vitro safety assessment methods, and a growing reliance on contract research organization (CRO)-led safety studies.

Download a free sample of the pharmaceutical safety assessment market report:
https://thebusinessresearchcompany.com/sample_request?id=29147&type=smp&name=Pharmaceutical%20Safety%20Assessment%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking beyond the immediate future, the market is expected to grow even more strongly, reaching $16.97 billion by 2030 with an improved CAGR of 8.5%. The forecast period's growth drivers include the rising dependence on computational safety assessments, the development of personalized medicines, accelerating demand for quicker regulatory approvals, increased integration of artificial intelligence (AI) in drug safety workflows, and stricter post-market surveillance requirements. Emerging trends that will shape this expansion consist of greater adoption of AI-based toxicity prediction tools, increased use of in-silico safety assessment models, deployment of real-time pharmacovigilance systems, growth of automated preclinical testing platforms, and a stronger focus on regulatory-compliant safety analytics.

Key Drivers Accelerating the Pharmaceutical Safety Assessment Market
One critical factor pushing the market forward is the increasing need for precise and efficient drug safety evaluations, which has become essential for regulatory compliance and minimizing risks. Expanding pharmaceutical pipelines and more complex drug candidates require rigorous safety assessments at preclinical and clinical stages to ensure patient safety and efficacy.

View the full pharmaceutical safety assessment market report:
https://www.thebusinessresearchcompany.com/report/pharmaceutical-safety-assessment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Another significant element is the rising adoption of innovative, technology-driven approaches such as computational models and AI tools. These advancements not only streamline safety evaluations but also enhance predictive accuracy, reduce costs, and shorten development timelines, making them highly attractive to pharmaceutical developers and regulators alike.

Leading Corporations Influencing the Pharmaceutical Safety Assessment Industry
Several prominent companies dominate the pharmaceutical safety assessment sector, including IQVIA Holding Inc., LabCorp (formerly Covance), Thermo Fisher Scientific (PPD), Charles River Laboratories, ICON plc, Parexel International Corp., Syneos Health, Eurofins Scientific SE, Wuxi Biologics Inc., SGS SA, Medpace Holdings Inc., Fujifilm Wako (Fujifilm Corp.), Pharmaron Beijing Co. Ltd., Inotiv (including Envigo), Evotec (Cyprotex), Intertek Group, Altasciences Inc., Aragen Life Sciences Ltd., CTI Clinical Trial and Consulting Inc., ChemDiv Inc., Frontage Laboratories, Medicilon Inc., Biotoxtech Co. Ltd., BioIVT, and Accelera Srl.

A notable recent development occurred in January 2025 when Groupe ProductLife S.A.S., a France-based life sciences company, acquired Stragen Services SAS, a pharmaceutical safety assessment specialist also located in France. This acquisition aims to strengthen ProductLife's pharmacovigilance and clinical safety capabilities, broaden its footprint in the European market, and enhance its ability to offer comprehensive regulatory and safety services to clients in pharma and biotech sectors.

How Technological Innovation is Shaping Pharmaceutical Safety Assessment
Cutting-edge technologies, especially AI-powered decision support systems, are becoming critical assets in improving the accuracy and efficiency of safety evaluations. These AI tools analyze complex datasets to provide faster and more reliable insights, helping to identify potential toxicities earlier and reduce subjectivity in pathology assessments.

For example, in April 2024, Charles River Laboratories teamed up with Deciphex, an Ireland-based firm, to launch the Patholytix Foresight platform. This AI-driven decision support system is designed to revolutionize toxicologic pathology in pharmaceutical safety assessment by quickly processing intricate preclinical pathology data. It offers features such as AI algorithms that detect tissue abnormalities, cloud-based collaboration capabilities, and scalable designs that speed up slide review times while improving data consistency and accuracy.

Pharmaceutical Safety Assessment Market Segmentation Overview
The pharmaceutical safety assessment market is segmented by several key criteria to better capture its diverse scope:
1) By Type:
- In-Vitro Safety Assessment
- In-Vivo Safety Assessment
- Computational Safety Assessment
2) By Drug Type:
- Biological Drugs
- Chemical Drugs
3) By Phase:
- Preclinical
- Clinical (Phases I, II, III)
- Post-Market Surveillance (Phase IV)
4) By End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Companies
- Academic and Research Institutions
- Contract Research Organizations (CROs)

Further detailed subcategories include:
- In-Vitro Safety Assessment: cell-based assays, organotypic models, tissue culture models, high-throughput screening
- In-Vivo Safety Assessment: rodent studies, non-rodent studies, toxicokinetic studies, carcinogenicity studies
- Computational Safety Assessment: quantitative structure-activity relationship (QSAR) modeling, physiologically based pharmacokinetic (PBPK) modeling, toxicity prediction software, in silico simulation studies

Together, these segments provide a thorough framework for analyzing the pharmaceutical safety assessment market and tracking its ongoing evolution.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.